# GENFIT (GNFT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/GNFT
## Company Profile
- Ticker: GNFT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: France and listed in the U
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### Liver-Disease Therapeutics and Diagnostics
GENFIT develops therapies and diagnostic technologies for liver diseases. Its portfolio combines commercial economics from a partnered product with internal programs in cholangiocarcinoma and acute-on-chronic liver failure.
### Iqirvo Economics
GENFIT receives milestones and royalties from Ipsen’s commercialization of Iqirvo in primary biliary cholangitis. Ipsen is also leading a Phase 3 study in primary sclerosing cholangitis, extending the molecule into another cholestatic liver disease.
### MASH Diagnostics
The company has developed non-invasive diagnostic technology for metabolic dysfunction-associated steatohepatitis. It is commercializing a laboratory-developed test and preparing in vitro diagnostic development to support patient identification as the treatment market expands.
### GNS561 in Cholangiocarcinoma
GNS561 is being evaluated in combination therapy for cholangiocarcinoma. Additional Phase 1b results are intended to inform a planned Phase 2 study.
### NTZ in ACLF
NTZ is the lead internal program for acute-on-chronic liver failure. GENFIT plans to move the asset into Phase 2 proof-of-concept development in a condition with high short-term mortality and limited treatment options.
## Why The Stock Is Moving

Current closing-price context is not available for GNFT.

## Future Catalysts

- Additional Phase 1b GNS561 combination data in cholangiocarcinoma expected in mid-2026.
- Initiation of Phase 2 development for GNS561 targeted in the second half of 2026.
- Initiation of a Phase 2 NTZ trial in ACLF expected in the second half of 2026, with data in 2027.

## Recent News
- 2026-08-03 14:32 EST — [GENFIT Answers its Investors – Episode #3 - August 3, 2026](https://biopharmsignal.com/news/GNFT/genfit-answers-its-investors-episode-3-august-3-2026-17ab91a1) — Source: GENFIT
- 2026-07-08 16:00 EST — [Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial](https://biopharmsignal.com/news/GNFT/genfit-half-year-report-of-liquidity-contract-with-cr-dit-industriel-et-commerci-c386698c) — Source: GENFIT
- 2026-07-02 16:05 EST — [GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH](https://biopharmsignal.com/news/GNFT/genfit-announces-u-s-medicare-coverage-and-future-reimbursement-for-nashnext-a-n-2769741e) — Source: GENFIT
- 2026-06-23 16:00 EST — [GENFIT: Positive Phase 1b Data with GNS561 in Combination Therapy in Heavily Pretreated Patients with Cholangiocarcinoma](https://biopharmsignal.com/news/GNFT/genfit-positive-phase-1b-data-with-gns561-in-combination-therapy-in-heavily-pret-b018e66c) — Source: GENFIT
- 2026-06-15 16:10 EST — [GENFIT: June 15, 2026 Combined Shareholders Meeting Results](https://biopharmsignal.com/news/GNFT/genfit-june-15-2026-combined-shareholders-meeting-results-d07ad996) — Source: GENFIT